Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH
EU approves Kyowa Kirin’s Crysvita for infants with XLH
10:31 ETSystemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
How Investors Are Reacting To Kyowa Kirin (TSE:4151) Real-World Data On Mogamulizumab’s Patient Benefits
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML | KURA Stock News
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML | KURA Stock News